Antibody Licensing Platform

CLDN6CDH6ALPPL2CCR8

Recommendation

More

Licensor’s Requirements

Autoimmune assets
Chinese Leading Enterprises
Format:

All Molecular Type

Stage:

Phase I-III

Modality:

Autoimmune

Data:

Phase Ib Completed

CD24
Leading biotech
Format:

All Molecular Type

Stage:

PCC

Modality:

mAb/BsAb

Data:

In-vivo Research Completed

ITGB6
ADC Leading Enterprise
Format:

All Molecular Type

Stage:

Lead

Modality:

ADC

Data:

Internalization Assay Completed

Boston
|
San Jose
|
Newark
|
Frankfurt
London
|
Basel
|
Beijing
|
Shanghai
Hangzhou
|
Suzhou
Stay Connected and Get Updates
Subscribe newsletter